Complete phenotypic recovery of an Alzheimer's disease model by a quinone-tryptophan hybrid aggregation inhibitor

PLoS ONE

Volumn 5, Issue 6, 2010, Pages

  Scherzer Attali, Roni ^a   Pellarin, Riccardo ^b   Convertino, Marino ^b   Frydman Marom, Anat ^a   Egoz Matia, Nirit ^a   Peled, Sivan ^a   Levy Sakin, Michal ^a   Shalev, Deborah E ^c   Caflisch, Amedeo ^b   Gazit, Ehud ^a   Segal, Daniel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 NAPHTHOQUINONE 2 YL TRYPTOPHAN; 1,4 NAPHTHOQUINONE DERIVATIVE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANISOTROPY; ARTICLE; BRAIN REGION; CIRCULAR DICHROISM; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; DROSOPHILA; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LARVAL STAGE; LIFESPAN; LOCOMOTION; MALE; MOLECULAR RECOGNITION; NERVE CELL CULTURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGOMERIZATION; PHENOTYPE; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN STRUCTURE; PROTEIN SYNTHESIS INHIBITION;

ALZHEIMER DISEASE; CIRCULAR DICHROISM; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PHENOTYPE; QUINONES; TRYPTOPHAN;

EID: 77956209768     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011101     Document Type: Article

References (65)

1. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. The Lancet9533: 387-403.
2. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, et al. (2005) Globalprevalence of dementia: a Delphi consensus study. The Lancet 9503:2112-2117.
3. Selkoe DJ (1991) The molecular pathology of Alzheimer's disease. Neuron 6:487-498.
4. Terry R (1994) Neuropathological changes in Alzheimer disease. Prog Brain Res101: 383-390.
5. Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiologyof Alzheimer's disease. Trends Phamac 12: 383-388.
6. Mann D (1989) Cerebral amyloidosis aging and Alzheimer's disease; acontribution from studies on Down's syndrome. Neurobiol Aging 10: 397-399.
7. Price D, Tanzi R, Borchelt D, Sisodia S (1998) Alzheimer's disease: geneticstudies and transgenic models. Annu Rev Genet 32: 461-493.
8. Van Leuven F (2000) Single and multiple transgenic mice as models forAlzheimer's disease. Prog Neurobiol 61: 305-312.
9. Fraser P, Yang D, Yu G, Levesque L, NishimuraM, et al. (2000) Presenilin structure, function and role in Alzheimer disease. Biochem Biophys Acta 1502: 1-15.
10. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al. (2005) Natural oligomers of the amyloid-b protein specifically disrupt cognitivefunction. Nat Neuroscience 1: 79-84.
11. Kirkitadze MD, Bitan G, Teplow DB (2002) Paradigm shifts in Alzheimer'sdisease and other neurodegenerative disorders: the emerging role of oligomericassemblies. J Neurosci Res 69: 567-577.
12. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PTJ (2002) Neurodegenerativedisease: amyloid pores from pathogenic mutations. Nature 418: 291.
13. Kayed R, Head E, Thompson JI, McIntire TM, Milton SC, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism ofpathogenesis. Science 300: 486-489.
14. Gazit E (2004) The role of prefibrillar assemblies in the pathogenesis of amyloiddiseases. Drugs Fut 29: 613-619.
15. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, et al. (2005) Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathologicalprotein in Alzheimer's disease. J Neurochemistry 3: 834-847.
16. Azriel R, Gazit E (2001) Analysis of the minimal amyloid-forming fragment ofthe islet amyloid polypeptide. An experimental support for the key role of thephenylalanine residue in amyloid formation. J Biol Chem 276: 34156-34161.
17. Gazit E (2002) A possible role for p-stacking in self-assembly of amyloid fibrils.FASEB J 16: 77-83.
18. Gazit E (2003) Global Analysis of Tandem Aromatic Octapeptide Repeats: TheSignificance of Aromatic-Glycine Motif. Bioinformatics 18: 880-883 (2002).
19. Reches M, Gazit E (2003) Casting metal nanowires within discrete selfassembledpeptide nanotubes. Science 300: 625-627.
20. Makin OS, Atkins E, Sikorski P, Johansson J, Serpell LCM (2005) Molecularbasis for amyloid fibril formation and stability. Proc Natl Acad Sci U S A 102:315-320.
21. Inouye H, Sharma D, Goux WJ, Kirschner DA (2006) Structure of core domainof fibril-forming PHF/Tau fragments. Biophys J 90: 1774-1789.
22. Colombo G, Daidone I, Gazit E, Amadei A, Di Nola A (2005) Moleculardynamic simulation of the aggregation of the core-recognition of the Isletamyloid polypeptide in explicit water. Proteins 59: 519-527.
23. Wu C, Lei HX, Duan Y (2005) The role of Phe in the formation of well-orderedoligomers of amyloidogenic hexapeptide (NFGAIL) observed in moleculardynamic simulation with explicit solvent. Biophys J 88: 2897-2906.
24. Tartaglia GG, Cavalli A, Pellarin R, Caflisch A (2004) The role of aromaticity, exposed surfaces and dipole moment in determining protein aggregation rates.Prot Sci 13: 1939-1941.
25. Zanuy D, Porat Y, Gazit E, Nussinov R (2004) Peptide sequence and amyloidformation: molecular simulation and experimental study of a human Isletamyloid polypeptide fragment and its analogs. Structure 12: 439-455.
26. Pawar AP, Dubay KF, Zurdo J, Chiti F, Vendruscolo M, et al. (2005) Predictionof ''aggregation-prone'' and ''aggregation susceptible'' regions in proteinsassociated with neurodegenerative diseases. J Mol Biol 350: 379-392.
27. Porat Y, Mazor Y, Efrat S, Gazit E (2004) Inhibition of Islet amyloid polypeptidefibril formation: a potential role for heteroaromatic interactions. Biochemistry43: 14454-14462.
28. Porat Y, Abramowitz A, Gazit E (2006) Inhibition of amyloid fibril formation bypolyphenols: structural similarity and aromatic interactions as a common. ChemBiol Drug Des 67: 27-37.
29. Bastianetto S, Krantic S, Quirion R (2008) Polyphenols as potential inhibitors ofamyloid aggregation and toxicity: possible significance to Alzheimer's disease.Mini Rev Med Chem 5: 429-435.
30. Rivièrea C, Richarda T, Quentina L, Krisab S, Mérillonb JM, et al. (2007) Inhibitory activity of stilbenes on Alzheimer's b-amyloid fibrils in vitro. Bioorg &Med Chem 15: 1160-1167.
31. Frydman-Marom A, Rechter M, Shefler I, Bram Y, Shalev DE, et al. (2009) Cognitive-Performance Recovery of Alzheimer's Disease Model Mice byModulation of Early Soluble Amyloidal Assemblies. Angew Chem Int Ed 48:1981-1986.
32. Cohen T, Frydman-Marom A, Rechter M, Gazit E (2006) Inhibition of amyloidfibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry 45:4727-4735.
33. Frew T, Powis G, Berggren M, Berggren M, Abraham RT, et al. (1995) Novelquinone antiproliferative inhibitors of phosphatidylinositol-3-kinase. AnticancerDrug Des 4: 347-359.
34. Gulielmo BJ, MacDougall C (2004) Pharmacokinetics of valaciclovir.J Antimicrob Chemother 6: 899-901.
35. Tomiyama T, Kaneko H, Kataoka, Asano S, Endo N (1997) Rifampicin inhibitsthe toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils andpreventing amyloid-cell interaction. Biochem J 322: 859-865.
36. Lieu VH, Wu JW, Wang SS, Wu CH (2007) Inhibition of amyloid fibrillizationof hen egg-white lysozymes by rifampicin and p-benzoquinone. Biotechnol Prog23: 698-706.
37. Pickhardt M, Gazova Z, von Bergen M, Khlistunova I, Wang Y, et al. (2005) Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helicalfilaments in vitro and in cells. J Biol Chem 280: 3628-3635.
38. Necula M, Kayed R, Milton S, Glabe CG (2007) Small Molecule Inhibitors ofAggregation Indicate That Amyloid b Oligomerization and FibrillizationPathways Are Independent and Distinct. J Biol Chem 282: 10311-10324.
39. Convertino M, Pellarin R, Catto M, Carotti A, Caflisch A (2009) 9,10-Anthraquinone hinders b-aggregation: How does a small molecule interfere withAb-peptide amyloid fibrillation? Prot Sci 18: 792-800.
40. Shrestha-Dawadi PB, Prativa B, Bittner S, Fridkin M, Rahimipour S (1996) Onthe Synthesis of Naphthoquinonyl Heterocyclic Amino Acids. Synthesis 12:1468-1472.
41. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB (2009) Amyloid betaproteinassembly and Alzheimer disease. J Biol Chem 284: 4749-4753.
42. Balbach JJ, Ishii Y, Antzutkin ON, Leapman RD, Rizzo NW, et al. (2000) Amyloid Fibril Formation by Ab16-22, a Seven-Residue Fragment of theAlzheimer's b-Amyloid Peptide, and Structural Characterization by Solid StateNMR. Biochemistry 39: 13748-13759.
43. Jarvet J, Damberg P, Bodell K, Eriksson LEG, Graslund A (2000) ReversibleRandom Coil to b-Sheet Transition and the Early Stage of Aggregation of theAb(12-28) Fragment from the Alzheimer Peptide. J Am Chem Soc 122:4261-4268.
44. Xu-Rong Q, Hiroshi A, Hiroshi N (2002) NMR and CD studies on theinteraction of Alzheimer beta-amyloid peptide (12-28) with beta-cyclodextrin.Biochem Biophys Res Commun 297: 1011-1015.
45. Gazit E (2005) Arrest of amyloid fibril formation associated to type II diabetes:structural and functional links to the mechanism of Alzheimer's b-amyloidfibrillization. Drug Des Rev 2: 115-119.
46. Cecchini M, Curcio R, Pappalardo M, Melki R, Caflisch A (2006) A MolecularDynamics Approach to the Structural Characterization of Amyloid Aggregation.JMB 357: 1306-1321.
47. Crowther DC, KIinghorn KJ, Miranda E, Page R, Curry JA, et al. (2005) Intraneuronal Ab, non-amyloid aggregates and neurodegeneration in adrosophila model of Alzheimer's disease. Neuroscience 132: 123-135.
48. Feany MB, Bender WW (2000) A Drosophila model of Parkinson's disease.Nature 404: 394-398.
49. Ganetzky B, Flanagan JR (1978) On the relationship between senescence andage-related changes in two wild-type strains of Drosophila melanogaster. ExpGerontol 13: 189-196.
50. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, et al. (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease byenhanced Abeta protofibril formation. Nat Neurosci 4: 887-893.
51. Iijima K, Chiang H, Hearn SA, Hakker I, Gatt A, et al. (2008) Ab42 mutantswith different aggregation profiles induce distinct pathologies in Drosophila.PloS one 3(2): e1703.
52. Wu C, Biancalana M, Shea JE (2009) Binding modes of thioflavin-T to thesingle-layer ß-sheet of the peptide self-assembly mimics. J Mol Biol 394:627-633.
53. Wu C, Wang Z, Lei H, Zang W, Duan Y (2007) Dual binding modes of Congored to amyloid protofibril surface observed in molecular dynamics simulations.J Am Chem Soc 129: 1225-1242.
54. Aue WP, Bartholdi E, Ernst RR (1976) Two-dimensional spectroscopy.Application to nuclear magnetic resonance. J Chem Phys 64: 2229.
55. Piotto M, Saudek V, Sklenar V (1992) Gradient-tailored excitation for singlequantumNMR spectroscopy of aqueous solutions. J Biomol NMR 2: 661-665.
56. Wagner R, Berger S (1996) Gradient-Selected NOESY-A Fourfold Reductionof the Measurement Time for the NOESY Experiment. J Magn Reson A 123:119-121.
57. Wüthrich K (1986) NMR of Proteins and Nucleic Acids. John Wiley & Sons, New York.
58. Honig B, Sharp K, Yang AS (1993) Macroscopic Models of Aqueous Solutions:Biological and Chemical Applications. J Phys Chem 97: 1101-1109.
59. Pearlmen DA, Case DA, Caldwell JW, Ross WS, Cheatham ITE, et al. (1995) AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations tosimulate the structural and energetic properties of molecules. Comp Phys 91: 6.
60. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al.(2004) UCSF Chimera - A Visualization System for Exploratory Research andAnalysis. J Comput Chem 25: 1605-1612.
61. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S (1983) CHARMM: A program for macromolecular energy, minimization, anddynamics calculations. J Comp Chem 4: 187-217.
62. Brooks BR, Brooks CL, Mackerell AD, Nilsson L, Petrella RJ, et al. (2009) CHARMM: the biomolecular simulation program. J Comput Chem 30(10):1545-614.
63. Ferrara P, Apostolakis J, Caflisch A (2002) Evaluation of a fast implicit solventmodel for molecular dynamics simulations. Proteins: Structure, Function, andBioinformatics 46: 24-33.
64. No K, Grant J, Jhon M, Scheraga H (1990a) Determination of net atomiccharges using a modified partial equalization of orbital electronegativity method.2. Application to ionic and aromatic molecules as models for polypeptides. J PhysChem 94: 4740-4746.
65. No K, Grant J, Scheraga H (1990b) Determination of net atomic charges using amodified partial equalization of orbital electronegativity method. 1. Applicationto neutral molecules as models for polypeptides. J Phys Chem 94: 4732-4739.